Related Experiment Video
Updated: Apr 21, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells
Xiaojun Ge1, Limei Zheng2, Min Huang3
1Department of Medical Oncology and Laboratory of Signal Transduction and Molecular Targeted Therapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Abstract:
The aim of the present study was to establish, characterize and elucidate the potential mechanisms of acquired gefitinb resistance, using the A549 human lung cancer cell line. A gefitinib-resistant A549 sub-clone was established by exposure to escalating gefitinib concentrations over a period of 16-24 months. Half maximal inhibitory concentration (IC50) values were quantified using a real time cytotoxicity assay. The expression profiles of the parent and resistant sub-clone A549 cells were detected using the µParaflo® Microfluidics Biochip microRNA (miRNA) Microarray. The ArrayPro software was used to analyze the differential expression levels of the miRNA, and bioinformatics software was used to predict the potential target genes of the differentially expressed miRNAs. Quantitative polymerase chain reaction (qPCR) was used to confirm the results of the miRNA microarray. A miRNA mimic was transfected into the gefitinib-resistant cells, in order to predict target gene interaction effects, following gefitinib treatment. Protein expression level differences were confirmed by western-blot analysis. Real time cytotoxicity assays revealed a 3-fold increase in the IC50 values of the gefitinib-resistant sub-clones, as compared with the parent cells. There were marked morphological differences between the parent and resistant cells. In the microarray analysis, the gefitinib-resistant sub-clones had 25 upregulated and 18 downregulated miRNAs, as compared with the parent cells. The qPCR revealed that miR-7 was significantly downregulated, which was concordant with the results of the microarray. The results of the present study suggest that miR-7 may significantly improve the sensitivity of cancer cells to gefitinib. The data presented in the present study provides an experimental basis and theory that miRNAs may be involved in acquired gefitinib-resistance of lung adenocarcinoma, and miR-7 may have potential clinical effects in the reversal of drug resistance.
Insights
Researchers developed gefitinib-resistant lung cancer cells to study acquired resistance mechanisms. They found that decreased miR-7 expression is linked to this resistance, suggesting miR-7 could reverse drug resistance in lung adenocarcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Acquired resistance to gefitinib is a significant challenge in treating lung adenocarcinoma.
- Understanding the molecular mechanisms underlying this resistance is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To establish and characterize gefitinib-resistant human lung cancer cells (A549).
- To elucidate the potential mechanisms of acquired gefitinib resistance, focusing on microRNA (miRNA) expression profiles.
- To investigate the role of specific miRNAs, particularly miR-7, in gefitinib resistance.
Main Methods:
- Establishment of gefitinib-resistant A549 sub-clones through prolonged drug exposure.
- Quantification of drug sensitivity using half maximal inhibitory concentration (IC50) values via real-time cytotoxicity assays.
- MicroRNA expression profiling using microfluidic biochip microarrays.
- Bioinformatic analysis to predict target genes of differentially expressed miRNAs.
- Validation of miRNA expression using quantitative polymerase chain reaction (qPCR).
- Functional analysis using miRNA mimics and western blotting to assess protein expression.
Main Results:
- Gefitinib-resistant cells exhibited a 3-fold increase in IC50 values and distinct morphological changes compared to parent cells.
- Microarray analysis revealed 25 upregulated and 18 downregulated miRNAs in resistant cells.
- Quantitative polymerase chain reaction confirmed significant downregulation of miR-7 in gefitinib-resistant cells.
- Functional studies indicated that miR-7 may enhance cancer cell sensitivity to gefitinib.
Conclusions:
- MicroRNAs are implicated in the acquired gefitinib resistance of lung adenocarcinoma.
- Downregulation of miR-7 is associated with gefitinib resistance.
- Restoring miR-7 levels may represent a potential therapeutic strategy to overcome gefitinib resistance in lung cancer patients.
More Related Videos
Related Concept Videos
MicroRNAs
MicroRNAs

